Kalaris Therapeutics (KLRS) Long-Term Debt Issuances (2024 - 2025)
Kalaris Therapeutics (KLRS) posted quarterly Long-Term Debt Issuances of $7.5 million for Q1 2025, up 50.21% year-over-year from $5.0 million in Q1 2024, and down 24.8% quarter-over-quarter from $10.0 million in Q4 2024.
Kalaris Therapeutics (KLRS) Long-Term Debt Issuances (2024 - 2025) Analysis & Trends
Kalaris Therapeutics' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at $7.5 million for Q1 2025.
- In Q1 2025, Long-Term Debt Issuances rose 50.21% year-over-year to $7.5 million; the TTM figure through Dec 2025 stood at $7.5 million (down 62.44% YoY), while the FY2025 annual figure was $7.5 million, down 62.44% from the prior year.
- Long-Term Debt Issuances for Q1 2025 stood at $7.5 million, down from $10.0 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $10.0 million in Q4 2024, with the low at $5.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 7.50 Mn |
| Mar 31, 2025 | 7.50 Mn |
| Dec 31, 2024 | 9.97 Mn |
| Dec 31, 2024 | 9.97 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Mar 31, 2024 | 4.99 Mn |
| Mar 31, 2024 | 4.99 Mn |